Replies to post #97330 on Biotech Values

[DewDiligence]

Irrespective of the patent ruling you cited, the arena for anti-CD20 biosimilars/Rituxan knockoffs has become unduly crowded, IMO. I completely discount the possibility that GTCB’s CD20 program will generate any value for shareholders.